Jiang et al recently reported that tumors with high TYRO3 expression exhibited anti-PD-1/PD-L1 resistance in a syngeneic mouse model and in patients who received anti-PD-1/PD-L1 therapy partially due to its suppressive effect on tumor cell ferroptosis. This evidence concerns the gene CD274 and neoplasm.